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Letter to the Editor
Predictive Value of the SYNTAX Score in Culprit
and Nonculprit Vessel Disease. Response
Valor predictivo de la puntuación SYNTAX en la lesión vascular
culpable y no culpable. Respuesta
To the Editor,
We read with great interest the Letter to the Editor by Levent
Cerit regarding the article ‘‘Multivessel Versus Culprit-only
Percutaneous Coronary Intervention in ST-segment Elevation
Acute Myocardial Infarction: Analysis of an 8-year Registry’’.1
As the author points out, there are several reasons that might
explain the worse prognosis of patients with ST-elevation acute
myocardial infarction and multivessel coronary disease, especially
when they have a high SYNTAX score. The burden of anatomic
coronary atherosclerosis, whether obstructive or nonobstructive, is
likely to be associated with more subclinical atherosclerotic
lesions that may rupture and cause an adverse clinical outcome.2,3
In patients with ST-elevation acute myocardial infarction and
multivessel disease who undergo primary percutaneous coronary
intervention of the culprit artery, quantification of the remaining
coronary artery disease by the residual SYNTAX score may help to
identify patients who are at increased risk for adverse events.4
Indeed, in our population, the residual SYNTAX score was an
independent predictor of major acute cardiovascular events and
all-cause mortality during follow-up; these data have been
submitted for publication.
Presently, there is no consensus regarding the management of
nonculprit lesions after primary-primary percutaneous coronary
intervention. The definition of a score, including anatomic
complexity of residual disease, to identify patients who will
clearly benefit from multivessel revascularization is desirable,
although probably utopic. There are still many questions that need
clarification: considering patient, operator and lesion specificities,
is standardization possible? Should we treat ischemic lesions,
vulnerable plaques or both? Should vulnerable patients (eg, those
with left ventricular dysfunction, renal disease, or diabetes) be
treated more aggressively?
Until we have an evidence-based strategy, clinical judgement
based on Heart Team discussion should be pursued in patients
with ST-elevation acute myocardial infarction and complex
multivessel disease.
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